SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Vasiliki Katsi, Ioannis Felekos, Stamatios Skevofilax, Constantina Aggeli, Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros, Cardiovascular Disease and Hepatitis C Virus Infection, Cardiology in Review, 2015, 23, 1, 11

    CrossRef

  2. 2
    Radhika Kumari, Mindie H Nguyen, Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1, Expert Opinion on Pharmacotherapy, 2015, 16, 5, 739

    CrossRef

  3. 3
    Josep Quer, Josep Gregori, Francisco Rodríguez-Frias, Maria Buti, Antonio Madejon, Sofia Perez-del-Pulgar, Damir Garcia-Cehic, Rosario Casillas, Maria Blasi, Maria Homs, David Tabernero, Miguel Alvarez-Tejado, Jose Manuel Muñoz, Maria Cubero, Andrea Caballero, Jose Antonio delCampo, Esteban Domingo, Irene Belmonte, Leonardo Nieto, Sabela Lens, Paloma Muñoz-de-Rueda, Paloma Sanz-Cameno, Silvia Sauleda, Marta Bes, Jordi Gomez, Carlos Briones, Celia Perales, Julie Sheldon, Lluis Castells, Lluis Viladomiu, Javier Salmeron, Angela Ruiz-Extremera, Rosa Quiles-Pérez, Ricardo Moreno-Otero, Rosario López-Rodríguez, Helena Allende, Manuel Romero-Gómez, Jaume Guardia, Rafael Esteban, Javier Garcia-Samaniego, Xavier Forns, Juan Ignacio Esteban, Y.-W. Tang, High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods, Journal of Clinical Microbiology, 2015, 53, 1, 219

    CrossRef

  4. 4
    Dennis Cada, Danial Baker, Ross Bindler, Ledipasvir/Sofosbuvir, Hospital Pharmacy, 2015, 50, 3, 224

    CrossRef

  5. 5
    Annarosa Floreani, Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C, Expert Opinion on Pharmacotherapy, 2015, 16, 6, 801

    CrossRef

  6. 6
    Stanislas Pol, Mark S. Sulkowski, Tarek Hassanein, Edward J. Gane, Lin Liu, Hongmei Mo, Brian Doehle, Bittoo Kanwar, Diana Brainard, G. Mani Subramanian, William T. Symonds, John G. McHutchison, Ronald G. Nahass, Michael Bennett, Ira M. Jacobson, Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed, Hepatology, 2015, 61, 6
  7. 7
    Ahmad Amanzada, Armin D Goralczyk, Lars Reinhardt, Federico Moriconi, Silke Cameron, Sabine Mihm, Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy, BMC Infectious Diseases, 2014, 14, 1, 503

    CrossRef

  8. 8
    J. C. Lin, F. Habersetzer, M. Rodriguez-Torres, N. Afdhal, E. J. Lawitz, M. S. Paulson, Y. Zhu, G. M. Subramanian, J. G. McHutchison, M. Sulkowski, D. L. Wyles, R. T. Schooley, Interferon  -Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response, Journal of Infectious Diseases, 2014, 210, 12, 1881

    CrossRef

  9. 9
    J. G. Stine, S. Cornella, N. L. Shah, Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir, Annals of the Rheumatic Diseases, 2014, 73, 10, e64

    CrossRef

  10. 10
    Andrea De Luca, Claudia Bianco, Barbara Rossetti, Treatment of HCV infection with the novel NS3/4A protease inhibitors, Current Opinion in Pharmacology, 2014, 18, 9

    CrossRef